The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Rapid Market Growth

• Current Market Size: Grew from $13.97 billion in 2023 to $15.34 billion in 2024.
• Growth Rate: Compound annual growth rate (CAGR) of 9.8%.
• Key Drivers:
  • Advancements in regenerative medicine.
  • Rising prevalence of chronic diseases.
  • Increased research and development initiatives.
  • Growing aging population.
  • Enhanced awareness and acceptance.

Forecasted Market Expansion

• Future Projections: Expected to grow to $23.13 billion by 2028.
• Growth Rate: CAGR of 10.8%.
• Growth Factors:
  • Expanding applications in oncology.
  • Innovations in personalized medicine.
  • Government support and funding.
  • Biotechnology collaborations and partnerships.
  • Clinical trials and regulatory approvals.

View More On The Stem Cell Market Report 2024 – https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

Major Trends in the Forecast Period

• Commercialization of Stem Cell Therapies: Increasing market availability.
• CRISPR Technology: Enhanced precision in genetic modifications.
• Regulatory Framework Development: Establishing guidelines for safety and efficacy.
• Investments in Stem Cell Research: Boosting technological advancements.
• Exosome Therapeutics: Emerging as a new focus area.

The Impact of Chronic Diseases

• Prevalence: Increasing number of chronic diseases worldwide.
• Stem Cell Therapy Applications:
  • Treat or prevent diseases.
  • Widely used in bone marrow transplants and umbilical cord blood-derived therapies.
  • Blood stem cell transplantation for blood and immune system disorders and post-cancer treatment recovery.
• Projected Increase: From 71.522 million people in 2020 to 142.66 million by 2050.

Key Players in the Market

• Leading Companies:
  • Danaher Corporation
  • Cryo-Cell International Inc.
  • Daiichi Sankyo Company Limited
  • Lonza Group Ltd.
  • PerkinElmer Inc.
  • CellGenix GmbH
  • China Cord Blood Corporation
  • Organogenesis Holdings Inc.
  • LifeCell International
  • AMAG Pharmaceuticals Inc.
  • Many more.

Advancements in iPSC Technology

• Induced Pluripotent Stem Cells (iPSC):
  • Derived from reprogrammed blood or skin cells.
  • Embryonic-like pluripotent state.
  • Ethical advantage: Not derived from human embryos.
• Notable Developments:
  • Japanese company Oksara’s iPS cell center.
  • Takara Bio’s Cellartis for disease modeling and drug discovery.

Strategic Acquisitions

• Catalent’s Acquisition of Rheincell Therapeutics GmbH:
  • Date: August 2021.
  • Purpose: To enhance Catalent’s cell therapy portfolio.
  • Outcome: Offering iPSC banks as a premium source for therapeutic development.
  • Rheincell Therapeutics GmbH: Specializes in GMP-compliant generation of human iPS cells.

Market Segmentation

• By Source:
  • Autologous (self-derived)
  • Allogeneic (donor-derived)
• By Product Type:
  • Adult Stem Cells
  • Human Embryonic Stem Cells
  • Induced Pluripotent Stem Cells
  • Other Products
• By Application:
  • Regenerative Medicine
  • Drug Discovery and Development

Regional Insights

• North America: Largest market in 2023, driven by advanced healthcare infrastructure and significant research investments.

The stem cell market is witnessing robust growth driven by technological advancements, expanding applications, and increased funding. The future looks promising with continued innovation and strategic partnerships, positioning the market for significant advancements in healthcare and therapeutic solutions.

Request A Sample Of The Global Stem Cell Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=2584&type=smp